JP2025503480A5 - - Google Patents
Info
- Publication number
- JP2025503480A5 JP2025503480A5 JP2024537849A JP2024537849A JP2025503480A5 JP 2025503480 A5 JP2025503480 A5 JP 2025503480A5 JP 2024537849 A JP2024537849 A JP 2024537849A JP 2024537849 A JP2024537849 A JP 2024537849A JP 2025503480 A5 JP2025503480 A5 JP 2025503480A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable region
- antigen
- heavy chain
- immunoglobulin heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292382P | 2021-12-21 | 2021-12-21 | |
| US63/292,382 | 2021-12-21 | ||
| PCT/US2022/082131 WO2023122659A2 (en) | 2021-12-21 | 2022-12-21 | Conditionally activated antigen binding polypeptide complexes and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503480A JP2025503480A (ja) | 2025-02-04 |
| JP2025503480A5 true JP2025503480A5 (https=) | 2026-01-05 |
Family
ID=86903785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537849A Pending JP2025503480A (ja) | 2021-12-21 | 2022-12-21 | 条件付きで活性化される抗原結合ポリペプチド複合体及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240059798A1 (https=) |
| EP (1) | EP4452317A4 (https=) |
| JP (1) | JP2025503480A (https=) |
| KR (1) | KR20240134257A (https=) |
| CN (4) | CN118251411A (https=) |
| AR (1) | AR128060A1 (https=) |
| AU (1) | AU2022420594A1 (https=) |
| CA (1) | CA3240079A1 (https=) |
| CL (1) | CL2024001850A1 (https=) |
| IL (1) | IL313770A (https=) |
| MX (1) | MX2024007393A (https=) |
| TW (1) | TW202334204A (https=) |
| WO (1) | WO2023122659A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| WO2025249301A1 (ja) * | 2024-05-27 | 2025-12-04 | 国立大学法人東京農工大学 | 多重特異性抗体、がん増殖抑制剤、ポリヌクレオチド及び発現ベクター |
| CN121248779A (zh) * | 2024-06-25 | 2026-01-02 | 冕屹立生物技术(上海)有限公司 | 靶向人cd3分子的抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI743461B (zh) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| US9458244B2 (en) * | 2012-12-28 | 2016-10-04 | Abbvie Inc. | Single chain multivalent binding protein compositions and methods |
| RS62437B1 (sr) * | 2015-10-25 | 2021-11-30 | Sanofi Sa | Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije |
| CA3020633A1 (en) * | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2018075564A1 (en) * | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| BR112020016944A2 (pt) * | 2018-02-20 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos |
| MX2021000307A (es) * | 2018-07-11 | 2021-09-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. |
| US12365722B2 (en) * | 2018-10-19 | 2025-07-22 | University Of Maryland, College Park | Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope |
| AU2019372673A1 (en) * | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| US11613576B2 (en) * | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 |
| TW202330594A (zh) * | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| IL313617A (en) * | 2021-12-17 | 2024-08-01 | Modex Therapeutics Inc | Antigen-binding polypeptide complexes containing extracellular regions of TNFSF ligands |
-
2022
- 2022-09-28 CN CN202280072889.7A patent/CN118251411A/zh active Pending
- 2022-09-28 CN CN202280078666.1A patent/CN118591388A/zh active Pending
- 2022-09-28 CN CN202280078695.8A patent/CN118317979A/zh active Pending
- 2022-12-21 IL IL313770A patent/IL313770A/en unknown
- 2022-12-21 US US18/069,529 patent/US20240059798A1/en active Pending
- 2022-12-21 AR ARP220103542A patent/AR128060A1/es unknown
- 2022-12-21 JP JP2024537849A patent/JP2025503480A/ja active Pending
- 2022-12-21 WO PCT/US2022/082131 patent/WO2023122659A2/en not_active Ceased
- 2022-12-21 CA CA3240079A patent/CA3240079A1/en active Pending
- 2022-12-21 MX MX2024007393A patent/MX2024007393A/es unknown
- 2022-12-21 AU AU2022420594A patent/AU2022420594A1/en active Pending
- 2022-12-21 CN CN202280089147.5A patent/CN118715247A/zh active Pending
- 2022-12-21 KR KR1020247024380A patent/KR20240134257A/ko active Pending
- 2022-12-21 EP EP22912696.6A patent/EP4452317A4/en active Pending
- 2022-12-21 TW TW111149263A patent/TW202334204A/zh unknown
-
2024
- 2024-06-19 CL CL2024001850A patent/CL2024001850A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025503480A5 (https=) | ||
| US10882922B2 (en) | Trispecific and/or trivalent binding proteins | |
| JP6622396B2 (ja) | 多重特異性抗体プラットフォームおよびその関連方法 | |
| US11421028B2 (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| JP2019522459A5 (https=) | ||
| JP2021531785A5 (https=) | ||
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| US20220396635A1 (en) | Trivalent binding molecules | |
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| CN105531374A (zh) | 双特异性cd3和cd19抗原结合构建体 | |
| US20240059798A1 (en) | Conditionally activated antigen binding polypeptide complexes and methods of use thereof | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| WO2020135804A1 (zh) | 异源二聚体融合蛋白 | |
| JP2023550419A5 (https=) | ||
| Brinkmann et al. | The making of multispecific immunoglobulins–a clinical perspective | |
| JP2022545368A5 (https=) | ||
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| RU2020115450A (ru) | Антитела к cd38 и комбинации с антителами к cd3 и cd28 | |
| JP2024531913A5 (https=) | ||
| RU2024102366A (ru) | Антитела к cd38 и комбинации с антителами к cd3 и сd28 | |
| RU2023128356A (ru) | Антитела к cd38 и комбинации с антителами к cd3 и сd28 |